Evofem Biosciences to Report Second Quarter 2022 Results and Provide Corporate Update on Thursday, August 4, 2022
Evofem Biosciences (Nasdaq: EVFM) will host a conference call on August 4, 2022, at 5:00 p.m. ET to discuss its second-quarter financial results and business highlights.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Evofem Biosciences (Nasdaq: EVFM) will host a conference call on August 4, 2022, at 5:00 p.m. ET to discuss its second-quarter financial results and business highlights. Investors can join the call by dialing (800) 285-6670 for U.S. participants or (713) 481-1320 for international participants. The call will also be available via a live webcast at evofeminvestorroom.com. The company specializes in women's sexual and reproductive health, with Phexxi® as its first FDA-approved product, expected to report clinical trial data this fall.
Details
News Market Reaction – EVFM
The recorded move for EVFM in the trading session of this news was -6.15%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
-- Conference Call Scheduled for 5:00 p.m. ET --
SAN DIEGO, July 28, 2022 /PRNewswire/ -- Evofem Biosciences, Inc., (Nasdaq: EVFM) will hold a webcast and conference call to discuss financial results and business highlights for the second quarter ended June 30, 2022 as follows:
Date: | Thursday, August 4, 2022 |
Time: | 5:00 pm. ET (2:00pm. PT) |
Live call: | (800) 285-6670 (U.S. toll-free) or |
Webcast (live and archived) and | https://evofeminvestorroomcom/2022Q2Results or |
Please connect to the webcast at least 15 minutes prior to the start of the call to download any software that may be required. If participating by phone, please dial in approximately 15 minutes prior to the start of the call.
About Evofem Biosciences
Evofem Biosciences, Inc., (Nasdaq: EVFM) is developing and commercializing innovative products to address unmet needs in women's sexual and reproductive health, including hormone-free, woman-controlled contraception and protection from chlamydia and gonorrhea. The Company's first FDA-approved product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is a hormone-free, on-demand prescription contraceptive vaginal gel. It comes in a box of 12 pre-filled applicators and is applied 0-60 minutes before each act of sex. The Company expects to report top-line data this fall from its registrational Phase 3 EVOGUARD clinical trial evaluating Phexxi for two potential new indications – prevention of chlamydia and prevention of gonorrhea in women. Learn more at phexxi.com and evofem.com.
Phexxi® is a registered trademark of Evofem Biosciences, Inc.
Investor Relations Contact
Amy Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
(917) 673-5775
View original content to download multimedia:https://www.prnewswire.com/news-releases/evofem-biosciences-to-report-second-quarter-2022-results-and-provide-corporate-update-on-thursday-august-4-2022-301595132.html
SOURCE Evofem Biosciences, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.